GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer

por Huntington, Kelsey E., Louie, Anna D., Srinivasan, Praveen R., Schorl, Christoph, Lu, Shaolei, Silverberg, David, Newhouse, Daniel, Wu, Zhijin, Zhou, Lanlan, Borden, Brittany A., Giles, Francis J., Dooner, Mark, Carneiro, Benedito A., El-Deiry, Wafik S.
Publicado 2023

GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer

por Huntington, Kelsey E., Louie, Anna D., Srinivasan, Praveen R., Schorl, Christoph, Lu, Shaolei, Silverberg, David, Newhouse, Daniel, Wu, Zhijin, Zhou, Lanlan, Borden, Brittany A., Giles, Francis J., Dooner, Mark, Carneiro, Benedito A., El-Deiry, Wafik S.
Publicado 2023

Therapeutic targeting of TRAIL death receptors

por Di Cristofano, Francesca, George, Andrew, Tajiknia, Vida, Ghandali, Maryam, Wu, Laura, Zhang, Yiqun, Srinivasan, Praveen, Strandberg, Jillian, Hahn, Marina, Sanchez Sevilla Uruchurtu, Ashley, Seyhan, Attila A., Carneiro, Benedito A., Zhou, Lanlan, Huntington, Kelsey E., El-Deiry, Wafik S.
Publicado 2023